Verrica Pharmaceuticals Inc
NASDAQ:VRCA

Watchlist Manager
Verrica Pharmaceuticals Inc Logo
Verrica Pharmaceuticals Inc
NASDAQ:VRCA
Watchlist
Price: 8.87 USD 6.87% Market Closed
Market Cap: 84.2m USD

Verrica Pharmaceuticals Inc
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Verrica Pharmaceuticals Inc
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Verrica Pharmaceuticals Inc
NASDAQ:VRCA
Operating Income
-$16.4m
CAGR 3-Years
11%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Operating Income
$24.9B
CAGR 3-Years
7%
CAGR 5-Years
4%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
Operating Income
$16.1B
CAGR 3-Years
11%
CAGR 5-Years
22%
CAGR 10-Years
19%
Pfizer Inc
NYSE:PFE
Operating Income
$18.3B
CAGR 3-Years
-23%
CAGR 5-Years
12%
CAGR 10-Years
3%
Merck & Co Inc
NYSE:MRK
Operating Income
$24.5B
CAGR 3-Years
7%
CAGR 5-Years
27%
CAGR 10-Years
11%
Eli Lilly and Co
NYSE:LLY
Operating Income
$26.4B
CAGR 3-Years
46%
CAGR 5-Years
34%
CAGR 10-Years
22%
No Stocks Found

Verrica Pharmaceuticals Inc
Glance View

Verrica Pharmaceuticals, Inc. engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. The company is headquartered in West Chester, Pennsylvania and currently employs 38 full-time employees. The company went IPO on 2018-06-15. The firm is focused on developing and commercializing treatments for skin diseases. The firm's lead product candidate, VP-102, is a drug-device combination of its topical solution of cantharidin, a widely recognized, naturally sourced agent to treat topical dermatological conditions, administered through its single-use precision applicator. The company is developing VP-102 for the treatment of molluscum contagiosum (molluscum), a highly contagious and primarily pediatric viral skin disease, external genital warts and common warts. The company also intends to develop its second cantharidin-based product candidate, VP-103, for the treatment of plantar warts, which are warts located on the bottom of the foot. The company also intends to develop its third product candidate, LTX-315, for the treatment of dermatological oncology indications, including non-metastatic melanoma and non-metastatic Merkel cell carcinoma.

VRCA Intrinsic Value
60.83 USD
Undervaluation 85%
Intrinsic Value
Price

See Also

What is Verrica Pharmaceuticals Inc's Operating Income?
Operating Income
-16.4m USD

Based on the financial report for Sep 30, 2025, Verrica Pharmaceuticals Inc's Operating Income amounts to -16.4m USD.

What is Verrica Pharmaceuticals Inc's Operating Income growth rate?
Operating Income CAGR 5Y
15%

Over the last year, the Operating Income growth was 79%. The average annual Operating Income growth rates for Verrica Pharmaceuticals Inc have been 11% over the past three years , 15% over the past five years .

Back to Top